HUTCHMED (China) Limited - ROE
HCM
Price:
$10.28
Market Cap:
$1.80B
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometr...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2016-03-16
Stock Exchange
NASDAQ
Ticker
HCM
PE Ratio
[3.88]
ROE
[37.04%]
Current Ratio
[4.96]
Dividend Yield
[0%]
Enterprise Value
[1.83B]
Dividend History
The ROE as of June 2026 (TTM) for HUTCHMED (China) Limited (HCM) is 37.04%
According to HUTCHMED (China) Limited’s latest financial reports and current stock price. The company's current ROE is 37.04%. This represents a change of 298.58% compared to the average of 9.29% of the last 4 quarters.
HUTCHMED (China) Limited (HCM) Historical ROE (quarterly & annually)
How has HCM ROE performed in the past?
The mean historical ROE of HUTCHMED (China) Limited over the last ten years is -10.38%. The current 37.04% ROE has changed -456.83% with respect to the historical average. Over the past ten years (40 quarters), HCM's ROE was at its highest in in the March 2025 quarter at 18.51%. The ROE was at its lowest in in the September 2022 quarter at -16.22%.
Average
-10.38%
Median
-12.51%
Minimum
-59.12%
Maximum
36.91%
HUTCHMED (China) Limited (HCM) ROE by Quarter and Year
Discovering the peaks and valleys of HUTCHMED (China) Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 643.52%
Maximum Annual ROE = 36.91%
Minimum Annual Increase = -191.21%
Minimum Annual ROE = -59.12%
| Year | ROE | Change |
|---|---|---|
| 2025 | 36.91% | 643.52% |
| 2024 | 4.96% | -64.01% |
| 2023 | 13.80% | -123.34% |
| 2022 | -59.12% | 199.74% |
| 2021 | -19.72% | -24.06% |
| 2020 | -25.97% | -27.85% |
| 2019 | -36.00% | 87.20% |
| 2018 | -19.23% | 232.10% |
| 2017 | -5.79% | -191.21% |
| 2016 | 6.35% | -33.80% |
HUTCHMED (China) Limited (HCM) Average ROE
How has HCM ROE performed in the past?
The current ROE of HUTCHMED (China) Limited (HCM) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
18.56%
5-year avg
-4.63%
10-year avg
-10.38%
HUTCHMED (China) Limited (HCM) ROE vs. Peers
How is HCM’s ROE compared to its peers?
HUTCHMED (China) Limited’s ROE is less than Bausch Health Companies Inc. (120.75%), greater than Perrigo Company plc (-50.65%), greater than IDEAYA Biosciences, Inc. (-13.96%), greater than Supernus Pharmaceuticals, Inc. (-2.73%), less than Catalyst Pharmaceuticals, Inc. (23.65%), greater than Scholar Rock Holding Corporation (-163.52%), greater than Adaptive Biotechnologies Corporation (-24.26%), greater than Mineralys Therapeutics, Inc. (-27.92%), greater than Cidara Therapeutics, Inc. (-60.15%), less than Kiniksa Pharmaceuticals, Ltd. (13.26%),
| Company | ROE | Market cap |
|---|---|---|
| 120.75% | $1.78B | |
| -50.65% | $1.42B | |
| -13.96% | $2.95B | |
| -2.73% | $2.58B | |
| 23.65% | $3.84B | |
| -163.52% | $5.67B | |
| -24.26% | $2.81B | |
| -27.92% | $1.63B | |
| -60.15% | $5.61B | |
| 13.26% | $4.14B |
Build a custom stock screener for HUTCHMED (China) Limited (HCM) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like HUTCHMED (China) Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
HUTCHMED (China) Limited (HCM) and other stocks custom spreadsheet templates
The easiest way to analyze a company like HUTCHMED (China) Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is HUTCHMED (China) Limited's ROE?
How is the ROE calculated for HUTCHMED (China) Limited (HCM)?
What is the highest ROE for HUTCHMED (China) Limited (HCM)?
What is the 3-year average ROE for HUTCHMED (China) Limited (HCM)?
What is the 5-year average ROE for HUTCHMED (China) Limited (HCM)?
How does the current ROE for HUTCHMED (China) Limited (HCM) compare to its historical average?